Insulin is a life-saving medication used to manage blood sugar levels in individuals with diabetes. It is administered via injections and helps regulate blood glucose (sugar) levels.
Hyderabad-based NiedlFree Technologies Private Limited has announced that Ozulin, an oral insulin spray to treat type 1 and 2 diabetes, will be available by 2025-26.
“NiedlFree will provide a huge relief to the diabetic population around the world,” said Directors Dr K Koteswara Rao, Viswanath Toshniwal, and Dr Jeetendra Ambulge in a joint statement.
Dr Koteswara Rao said that the team saw potential for their animal care division as well, with the global pet care market for diabetes estimated to be around $2 billion in 2022.
The directors added that the total revenues from diabetes drugs around the world in 2022 was said to be $78 billion (₹6,24,000 crore — type 1 and type 2 combined).
Since insulin is the preferred drug of choice for most diabetics, nasal or oral insulin intake provides comfort as an effective alternative to all other diabetes drugs, Dr Rao claimed.
“We are establishing a facility in Hyderabad to produce this Insulin product and, on a pilot project basis, we have got global patents for this novel oral insulin,” he further announced.
“With this success, we are poised to extend this to other injectable formulas across various medical segments, targeting specifically those conditions that are debilitating,” he added.